Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 11, 2024

Humanized Anti–PD-1 Monoclonal Antibody Retifanlimab in Patients With Solid Tumors

ESMO Open

 

Additional Info

ESMO Open
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
ESMO Open 2024 Mar 01;9(3)102387, AM Di Giacomo, M Schenker, J Medioni, S Mandziuk, M Majem, G Gravis, M Cornfeld, S Ranganathan, S Lou, T Csoszi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading